4597 Share Price Performance
JP¥0
-42.00 (-100.00%)
Price JP¥0
Share Pricen/a
Analysis Article • Apr 17
Solasia Pharma K.K. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
4597 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Solasia Pharma K.K. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 13, 2026
- -3.26
- 50.49%
- -217.32%
- 0%
About 4597
- Founded
- 2006
- Employees
- 22
- CEO
- WebsiteView website
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
